Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance

N/AUnknownNCT01710761

University of Texas at Austin16 enrolled

Overview

Acute supplementation of Neo40(TM), a nitrate lozenge, will improve cycling performance

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Healthy

Interventions

PlaceboDIETARY_SUPPLEMENT

Same form factor and flavor as test lozenge but contains no active ingredients

Nitrate supplement with caffeineDIETARY_SUPPLEMENT

Lozenge consisting of beetroot and 75 mg caffeine

Eligibility

Sex: ALLMin age: 21 YearsMax age: 49 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Regular commuter cyclist or spin class participant * Male (VO2max \< 50) or Female (VO2max \< 45) * Healthy * Blood pressure below 140/90 * Non-smoker Exclusion Criteria: * Does not cycle 2-3 times/week * Regular consumption of performance-enhancing substances * Type I or Type II diabetes * Renal, hepatic or cardiac disease * Current infectious disease

Locations (1)

The University of Texas at Austin

Austin, Texas, United States

Outcomes

Primary Outcomes

Improved Time Trial Performance

Participants will cycle 20 min at increasing intensity: 8 min at 55% VO2max, 6 min at 65% VO2max, 6 min at 75% VO2max. The 20 km time trial consists of rolling hills.

Time frame: After 20 min steady-state cycling

Secondary Outcomes

Improved work efficiency

Expired gases will be collected and compared to expected VO2. Blood will be collected prior to treatment, prior to exercise and during each cycling intensity to analyze lactate accumulation.

Time frame: During 20 min steady-state cycling

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.